Johanna. you, Thank
Trodelvy's highlighting The spanning the in a diverse Trodelvy cancer, Phase clinical virology, first-line pipeline with II data alternative broadly, potential of increasingly release patients. non-small and much-needed bring of inflammation. promising clinical More highlight our continue to pembrolizumab XX of our for treatment oncology our combination to quarter was ongoing cell programs, metastatic for third we in lung progress
Starting virology programs Slide with our XX. on
have enrollment we have in adolescent including that underway I'm girls for We our long-acting inhibitor, Phase and lenacapavir prevention X capsid clinical lenacapavir XX than PURPOSE-I programs pleased in trial, Phase PrEP. women. for III studies share III to our with completed earlier anticipated evaluating young
in PURPOSE of PURPOSE-II III or XXXX and trials from cis-man and opportunity men ahead both to could have we trial and and continues non-binary enroll Phase late share to Our people data an in well, schedule. transwomen one
available our for potentially making for first the lenacapavir in prevention PrEP. in late We regimen monthly XXXX first X lenacapavir are approval dosing targeting
Turning to treatment.
progress on make continue X Of candidates, candidate already remaining for the in We Phase X. strong are X or lenacapavir. evaluating X partners to
suppressed combination integrase living We including of a be least trial our combined II to I X our with inhibitor our And at once-weekly GS-XXXX, of from data combination in XXXX, people expect trial, of for plan and from with bictegravir share We biologically forward evaluating and share Phase share We're updates oral from enrollment HIV. to another we both months to on Phase once-daily ARTISTRY-I lenacapavir oral long-acting well lenacapavir. these treatment-experienced II on to we the lenacapavir+bNAbs program you results every XXXX, to the development. also next at to our Phase next is these early of progressing very in our evaluating for trials is advancing into dosed conference and a expect year. X pleased phase look update programs program
the continues this together, prevention treatment our all transform has confidence support HIV to Putting and lenacapavir that data our globally. potential to
growing and able that clinical launch unique real-world potent trial data drug-to-antibody X into only the has tumor to more a XX,XXX X indications evidence Trodelvy construct. conjugate benefit Turning both we're Trodelvy tumor payload also than is through approach seeing Trodelvy's only remains marketed particular, patients date, been To is to survival In on approved a that in delivered to ADC TROP-X have With for Slide deliver our ago. antibody-drug oncology achieve taking and its ADC types, of indications. first to across said, we're developments meaningful to X only the supporting Trodelvy since not overall the but XX directly XX. clinical hydrolyzable its years Trodelvy's ratio high SNXX microenvironment highly linker. the across
As we shown a to of therapy. continue Trodelvy Trodelvy regards date, has data potentially types to across ILD more look forward a safety result, in in and studies stomatitis. with our emerging profile and We XXXX expand tumor to as differentiated lines to sharing Trodelvy
demonstrating data clinical for Trodelvy across Trodelvy clinical or several comprehensive more types. signals XXXX, of indications. XX shared sets for activity In across several active planned X program trials tumor of Our development consists clear than we've
ASCO past endometrial presented II and in relapsed meeting, June, we trial. TROPiCS-XX data demonstrated in for basket encouraging Phase For patients in ORR data or refractory example, this preliminary that PFS the the Trodelvy cancer
More ESMO lung additional the carcinoma treated recently, from cell and small showing TROPiCS-XX, refractory squamous cancer. meeting, in at both or neck promising previously relapsed we and cell early head ORR data extensive-stage presented
EVOKE-XX in an high This and and with including reported of pembro proof cohort, World demonstrated cancer. compares monotherapy in plus rates historical metastatic response to strong respectively. favorably the the KEYNOTE-XXX, data Trodelvy at Lung pembro pembro concept Trodelvy unconfirmed Slide In clear plus establishing lung for responses. of first-line XX% on cell non-small shown September from We PD-LX benchmark in XX% XX, ORR of XX%, KEYNOTE-XXX
that TPS chemotherapy. with As patients to plus a our PD-LX-high than XX% cohort in metastatic ORR PD-LX first-line reminder, pembro similar less EVOKE-XX lung cancer Phase III also we currently non-small Preliminary study. trials enrolling are from of encouraging, XX%, cell has demonstrating registrational previous data been an evaluated the
sharing first-line into EVOKE-XX These metastatic cell cancer squamous both cell from highlight forward results the inform We're will that Trodelvy broader patient cancer to histologies further populations non-squamous levels. expand and looking non-small across non-small first-line all to and expression patients. our across plans lung in PD-LX of lung efficacy analysis pembro
XX%. II an Moving program the regimen ORR, Phase initial to a first-line in the and session arm dom and of to PD-LX an with plus an adverse with upper on of FOLFOX the to FOLFOX. Slide well EDGE-Gastric an care that tumors, X pleased an GI The X-month PFS zim in found generally was high metastatic tolerated plenary ORR to of that addition patients update responses to was cancer. TIGIT profile earlier XX% In anti-PD-X chemo zim the encouraging showed event our ASCO study including unconfirmed dom study XX, impressive XX% the and We're today. X-month similar standard PFS added presented of XX% and see was was
similar the anti-TIGIT in program. ongoing gastric III the broader adenocarcinoma results population our first-line trial and These junction increase in confidence registrational gastroesophageal and esophageal STAR-XXX our Phase
tumor in into including every cancer. in we we're types has that work cancer dom and efficacy not the lung type, advanced see have tumor cell studies shown encouraging tolerability upper Phase non-small will and GI III anti-TIGIT Although excited first-line to
cell XX. therapy to Slide Turning on
are cell to to more expand to of new benefits We or patients new therapy X continuing indications lines, ongoing settings. the trials work in with earlier even
cell well as are invariant cell We donor early-stage also therapies. healthy killer pipeline allogeneic CARTs, natural exploring where as therapies including an and and killer we iPSC-derived extensive have natural T
world's we patients. maintain manufacturer therapies, manufacturing cell for Beyond innovation continue in rapid as to treatment drive position and more our invest to leading therapy the
are disease This of emerging myeloma the where We diseases. difficult expertise apply have includes therapy, treatment our we multiple will continue to where to to in areas potential we cell explore II CART-ddBCMA deliver in services CART-ddBCMA Phase pleased we trial, to our profile therapeutic share in has enrollment, be to the and resumed confidence that patients. the benefit IMAGINE-X of to the able
months where the respond X/X end, release abstract further longer next look the Hematology data safety reached. in CART-ddBCMA's upcoming Society ongoing last and benefits ASH In durability robust To evidence a we that both of December. data follow-up not has trial, are additional survival of survival clinical the profile of American median continue efficacy the XX week's the and been Phase in patients the meeting body long-term I unveiled in reinforce to follow-up even highlighting month. yet of strengthening to further and and Tecartus meeting Yescarta of median forward We at meantime, the and
Finally, to and Andy, clinical on before shown Slide on milestones hand over the progress is XX. I team's key XXXX
programs and discontinued portfolio, all partial both a And ENHANCE-X other clinical benefit evaluate the progress evaluating programs clinical with magrolimab. continue for The expected unfit remains magrolimab is analysis. of in our patients As way and large the trials not been ENHANCE AML, have study the diverse futility tumor we hold and they ENHANCE-X Phase we hope and under will will. solid to on this based frontline, II
some regards we XXXX, forward look of to sharing from to ARTISTRY-I XXXX. as With medical conference for data the in a milestones at remaining referenced previously,
for our expect For our we to first have PURPOSE-IV patient the studies, the in and by year. continue this to of trials clinical end PURPOSE-III prevention HIV
we Additionally, year. on to for our evaluating initiate this first-in-class potential PALEKONA TPL-X our ulcerative Phase trial track colitis later II remain inhibitor
for our inhibitor oral of Our TPL-X represents agents one many inflammation.
potential our share will it beyond year for it's due be clear a filings and milestones for for we CART-ddBCMA. obeldesivir, but already XXXX Trodelvy rich XXXX, updates Looking updates data that lenacapavir, or target Gilead, will including regulatory course, in
to hand Andy? I'll With call that, the Andy. over
